Company / Capital Expenditures
CytomX Therapeutics, Inc. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$220.0K
FY2025
5-year range
$220.0K / $1.7M
FY2021-FY2025
Trend
-29.0%
vs FY2024
Sector context
#157 of 194
Health Care
What the data says
CytomX Therapeutics, Inc.'s capital expenditures of $220,000 is lower than 81% of companies in the Health Care sector (FY2025). Capital Expenditures has declined for 3 consecutive years, from $2M in FY2022 to $220,000 in FY2025.
Based on SEC 10-K filings.
$220,000 in FY2025 with a 5-year CAGR of -37.5%.
Declined from $840,000 to $220,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -49.8%
- 5-Year CAGR
- -37.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 19% in Health CareTop 81% of 194This company $220.0K Sector average $117.5M
▼
-99.8% below sector average
Key checks
Key Insights
- CytomX Therapeutics, Inc.'s capital expenditures has declined for 3 consecutive years.
- 5-year CAGR of -37.5%, indicating a declining trend.
- In FY2025, capital expenditures decreased 29.0% year-over-year.
- Ranks #157 out of 194 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.68 (distress zone, below 1.8 threshold)
- Strong profit margin: 23.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $220.0K | -29.0% |
| FY2024 | $310.0K | -63.1% |
| FY2023 | $840.0K | -51.7% |
| FY2022 | $1.7M | +8.1% |
| FY2021 | $1.6M | -30.3% |
| FY2020 | $2.3M | -34.0% |
| FY2019 | $3.5M | -7.7% |
| FY2018 | $3.8M | +143.0% |
| FY2017 | $1.6M | -28.4% |
| FY2016 | $2.2M | +197.3% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026